Study finds best use of insulin as diabetes progresses

Oct 23, 2009
Study finds best use of insulin as diabetes progresses
Professor Rury Holman of the Diabetes Trials Unit led the study.

(PhysOrg.com) -- A large-scale trial in diabetes patients has provided new evidence on how best to add insulin to standard drugs to control blood sugar levels as type 2 diabetes progresses.

The University of Oxford research was published in the to coincide with presentation of the final trial results at the World Diabetes Congress in Montreal, Canada.

Patients who added insulin, either through once-a-day (basal) insulin injections or three injections at mealtimes, to their oral anti-diabetes drugs showed better control of their levels than those adding twice daily insulin injections.

Those starting with a single insulin injection each day also had fewer hypoglycaemic episodes (when blood sugar levels are too low) and gained less weight.

‘Type 2 diabetes is a progressive condition with the majority of patients eventually requiring insulin therapy,’ says Professor Rury Holman, principal investigator of the study and director of the Diabetes Trials Unit at Oxford University. ‘This large-scale study strengthens guidelines recommending adding a basal insulin to oral agents when glycaemic targets are not met.’

Improved control of blood sugar levels is known to reduce the risk of complications in type 2 diabetes, such as and loss of vision from eye disease. As type 2 diabetes progresses, the standard oral therapy will typically need to be escalated repeatedly over time.

Eventually, the majority of patients will require insulin but there remains uncertainty as to which regimen of insulin injections should be used when oral drugs become insufficient. There is no clear consensus about whether to start with insulin therapy three times a day with meals, injections twice a day, or a long-acting once-a-day insulin injection.

The researchers set out to find which pattern of treatment resulted in the best control of blood sugar levels. Their three-year, randomised controlled trial compared different insulin regimens in 708 patients with whose current doses of anti-diabetic drugs were not proving sufficient.

During the first year, the patients were randomised to one of the three insulin courses. During the second and third years, those who were still not achieving their glucose targets were moved to more complex insulin regimens.

Dr Jonathan Levy, lead clinician at the Oxford Centre for Diabetes, Endocrinology and Metabolism and co-principal investigator said: ‘Starting with a basal insulin and adding a mealtime if required provided the best combination of effectiveness, safety and treatment satisfaction’.

‘These results will help patients and healthcare professionals in routine clinical practice to decide which treatment is most suitable for the individual,’ added Dr Andrew Farmer, co-principal investigator at the Department of Primary Health Care.

Provided by Oxford University (news : web)

Explore further: Researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies

add to favorites email to friend print save as pdf

Related Stories

Self-monitoring of blood glucose

Sep 29, 2009

Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment. This is the view advocated by Michael Nauck of the Bad Lauterberg Diabetes Center and his coauthors in ...

FDA approves new diabetes treatment

Oct 17, 2006

The U.S. Food and Drug Administration has approved the use of Januvia tablets as the first in a new class of diabetes drugs.

Home glucose tests may not help

Jun 28, 2007

A British study shows patient monitoring of glucose levels may not be essential to controlling type 2 diabetes for those not taking insulin.

Recommended for you

One route to malaria drug resistance found

2 hours ago

Researchers have uncovered a way the malaria parasite becomes resistant to an investigational drug. The discovery, at Washington University School of Medicine in St. Louis, also is relevant for other infectious ...

Protein therapy successful in treating injured lung cells

2 hours ago

Cardiovascular researchers at The Ohio State University Wexner Medical Center have successfully used a protein known as MG53 to treat acute and chronic lung cell injury. Additionally, application of this protein proved to ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Ant
not rated yet Oct 23, 2009
As a type 2 sufferer on insulin I also find the basal insulin (once daily 9pm)better as when on the twice daily injections I had a number of hypo episodes 2 of which left me unconsious in our local park. This is very problematic when the individual is a driver (as most are) and can lead to the loss of licence for 12 months. However after changing to a once daily dose of the long lasting insulin the glucose levels are much more even and I have not had a hypo episode for over 12 months.